EX-99.1 2 ea028661101ex99-1.htm PRESS RELEASE BY MODULAR MEDICAL, INC. DATED APRIL 16, 2026 Exhibit 99.1 Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, CA / ACCESSWIRE / April 16, 2026 / Modular Medical, Inc. (“Modular Medical” or the “Company”) (NASDAQ: MODD), a leader in innovative, patient-centric insulin delivery, today announced that it has received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement. The letter noted that, as of April 14, 2026, the Company evidenced a closing bid price of its common stock in excess of the $1.00 minimum requirement for the last 10 consecutive trading days. Accordingly, the Company has regained compliance with Nasdaq Marketplace Rule 5550(a)(2) and Nasdaq considers the matter closed. About Modular Medical Modular Medical, Inc. (Nasdaq: MODD) is a development-stage medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and effi…
Open exhibit ↗Current Report · Items 8.01, 9.01 · 8-K
Modular Medical, Inc.
MODDNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On April 16, 2026, Modular Medical, Inc. (the “Company”) issued a press release announcing the Company received a notification letter on April 15, 2026 from the Listing Qualifications Department of the Nasdaq Stock Market notifying the Company that it had regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2) (the “Minimum…
Company context
We are a pre-revenue medical device company focused on the design, development and commercialization of innovative insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. Through the creation of a novel two part patch pump, we seek to fundamentally alter the trade-offs between cost and complexity and access to the higher standards of care that presently-available insulin pumps provide. By simplifying and streamlining the user experience from introduction, prescription, reimbursement, training and day-to-day use, we seek to expand the wearable insulin delivery device market beyond the highly motivated “super users” and expand the category into the mass market. The product seeks to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets. In January 2024, we submitted a 510(k) premarket notification to the United States Food and Drug Administration (the “FDA”) for our initial product, our MODD1, and, in September 2024, we received FDA clearance to market and sell our MODD1 pump in the United States. In August 2025, we announced the first human use of our MODD1 pump delivering insulin to a human patient. In addition, in August 2025, we announced our next-generation patch pump, branded as Pivot. We submitted a 510(k) premarket notification to the FDA for our Pivot product on November 13, 2025, when the United States government shutdown ended. We intend to initiate our commercial launch